

This CME/CE/CPE accredited supplement is jointly provided by



Journal of the Advanced Practitioner in Oncology

The Role of the Advanced Practitioner in Maintaining Adherence in Patients on Oral Oncolytics

A continuing education activity for nurse practitioners, PAs, clinical nurse specialists, advanced degree nurses, oncology and hematology nurses, pharmacists, and physicians.

Release date: December 8, 2017

Estimated time to complete activity: 1.0 hour

Expiration date: December 7, 2018

Annenberg Center for Health Sciences at Eisenhower

39000 Bob Hope Drive, Dinah Shore Bldg.

Rancho Mirage, CA 92270

Voice: 760-773-4500

Fax: 760-773-4513

E-mail: contactce@annenberg.net

Journal of the Advanced Practitioner in Oncology

94 North Woodhull Road

Huntington, NY 11743

Voice: 631-692-0800

Fax: 631-692-0805

E-mail: ckiffer@hbbside.com

© 2017, Annenberg Center for Health Sciences at Eisenhower. All rights reserved.

This activity is supported by unrestricted educational grants from AstraZeneca; Bayer HealthCare Pharmaceuticals Inc.; Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Novartis Pharmaceutical Corporation; and Taiho Oncology, Inc.

Faculty

Diane Cope, PhD, ARNP-BC, AOCNP®, Florida Cancer Specialists and Research Institute

Kimberly M. Hicks, PharmD, MHA, HHCS Health Group of Companies

John Novak, CHA, PA-C, Rocky Mountain Cancer Centers and University of Colorado School of Medicine

Susan Scherer, RN, BSN, OCN®, RN Cancer Guides Solutions

Activity Rationale and Purpose

The issue of patient adherence to oral medications as part of cancer treatment regimens continues to evolve in importance in the US. Almost 40% of the total cost of targeted therapies in the US are now for oral formulations, up from 26% in 2010. Within a busy oncology practice, there is often a lack of dedicated resources to devote to following up with patients about sticking with their oral treatment plans, assessing patients who may be at risk for not taking oral treatments as prescribed, or advocating for co-pays or other financial resources available to patients. Advanced practitioners (APs) in oncology are well-positioned to intervene and make a significant difference in motivating patients to continue their oral treatment regimens. This education will focus on how APs can overcome a variety of barriers for patient nonadherence to oral therapies and encourage patients to continue their regimens.

Intended Audience

The activity's target audience will consist of nurse practitioners, PAs, clinical nurse specialists, advanced degree nurses, oncology and hematology nurses, pharmacists, and physicians.

Learning Objectives

After completing this educational activity, participants should be able to:

1. Demonstrate an increased understanding of the potential adherence barriers for patients whose treatment regimens include an oral medication
2. Describe the role of various stakeholders who practice collaboratively to assess patients at high risk for nonadherence with their oral cancer medications
3. Develop a strategy for advanced practitioners for improving patient adherence with oral oncology medications in their own practice
4. Counsel and educate patients on appropriate resources available for medication copayments

Continuing Education

Statement of Credit—Participants who successfully complete this activity (including the submission of the post-test and evaluation form) will receive a statement of credit.



Physicians. The Annenberg Center for Health Sciences at Eisenhower has been awarded Accreditation with Commendation by the Accreditation Council for Continuing Medical Education (ACCME®).

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the Annenberg Center for Health Sciences at Eisenhower, the Advanced Practitioner Society for Hematology and Oncology, and the Journal of the Advanced Practitioner in Oncology. The Annenberg Center is accredited by the ACCME to provide continuing medical education for physicians.

The Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 1.0 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.



Nurses. The Annenberg Center for Health Sciences at Eisenhower is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

A maximum of 1.0 contact hour may be earned for successful completion of this activity.

Provider approved by the California Board of Registered Nursing, Provider No. 13664, for 1.0 contact hour.



Pharmacists. This knowledge-based accredited educational activity is intended for pharmacists involved in the care of cancer patients. This educational activity is provided by the Annenberg Center for Health Sciences at Eisenhower.

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program is assigned ACPE Universal Program #0797-9999-17-107-H01-P. This program is designated for up to 1.0 contact hour (0.1 CEU) of continuing pharmacy education credit.

Financial Disclosures

All individuals in positions to control the content of this program (eg, planners, faculty, content reviewers) are expected to disclose all financial relationships with commercial interests that may have a direct bearing on the subject matter of this continuing education activity. Annenberg Center for Health Sciences at Eisenhower has identified and resolved all conflicts of interest in accordance with the ACHS policies and procedures. Participants have the responsibility to assess the impact (if any) of the disclosed information on the educational value of the activity.

Disclosures

FACULTY

Diane Cope, PhD, ARNP-BC, AOCNP®, has nothing to disclose.

Kimberly M. Hicks, PharmD, MHA, has nothing to disclose.

John Novak, CHA, PA-C, serves on speakers bureaus for Amgen, Lexicon, and Pfizer, and has acted as a consultant for bioTheranostics.

Susan Scherer, RN, BSN, OCN®, has nothing to disclose.

ANNENBERG CENTER FOR HEALTH SCIENCES AT EISENHOWER

John Bayliss, VP, Business Development, spouse is an employee of Amgen, Inc; **Charles Willis, Director, Continuing Education**, consults for Pfizer Inc.; all other staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.

LEAD NURSE PLANNER

Dorothy Caputo, MA, BSN, RN, has nothing to disclose.

PLANNERS

Jeannine Coronna has nothing to disclose.

Joseph Cupolo has nothing to disclose.

Claudine Kiffer has nothing to disclose.

Patricia McLafferty has nothing to disclose.

Lynn Rubin has nothing to disclose.

Pamela Hallquist Viale, RN, MS, CNS, ANP, has nothing to disclose.

Annie Yueh has nothing to disclose.

CONTENT REVIEWERS

Kate D. Jeffers, PharmD, BCOP, has served on the speakers bureau for Amgen and advisory boards for Takeda and Tesaro.

Carol Blecher, RN, MS, AOCN®, APNC, CBPN-C, CBCN, has nothing to disclose.

Disclaimer

This activity has been designed to provide continuing education that is focused on specific objectives. In selecting educational activities, clinicians should pay special attention to the relevance of those objectives and the application to their particular needs. The intent of all Annenberg Center for Health Sciences at Eisenhower educational opportunities is to provide learning that will improve patient care. Clinicians are encouraged to reflect on this activity and its applicability to their own patient population.

The opinions expressed in this activity are those of the faculty and reviewers and do not represent an endorsement by Annenberg Center for Health Sciences at Eisenhower of any specific therapeutics or approaches to diagnosis or patient management.

Product Disclosure

This educational activity may contain discussion of published as well as investigational uses of agents that are not approved by the US Food and Drug Administration. For additional information about approved uses, including approved indications, contraindications, and warnings, please refer to the prescribing information for each product.

How to Earn Credit

To access the learning assessment and evaluation form online, visit <http://surveys.edmeasures.com/s3/Oral-Oncolytics>

Statement of Credit: Participants who successfully complete this activity (including scoring of a minimum of 70% on the learning assessment) and complete and submit the evaluation form will be able to download a statement of credit.